Rachel Riley
Family · Danvers, MANPI 1053482562
Payments from drug & device makers
Across 90 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$242
- Regeneron Healthcare Solutions, Inc.$222
- Insulet Corporation$159
- Novo Nordisk$106
- Amgen$102
- Takeda Pharmaceuticals U.S.A., Inc.$98
- plus $901 from 21 others
What the payments were for
- Food & beverage$1,831100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $242 |
| Regeneron Healthcare Solutions, Inc. | 9 | $222 |
| Insulet Corporation | 3 | $159 |
| Novo Nordisk | 6 | $106 |
| Amgen(2 entities) | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Stryker | 6 | $97 |
| Abbott | 4 | $79 |
| AstraZeneca | 1 | $76 |
| Ardelyx, Inc. | 3 | $74 |
| Johnson & Johnson | 3 | $68 |
| Medtronic | 2 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Lilly USA, LLC | 3 | $54 |
| Radius Health, Inc. | 2 | $50 |
| Tandem Diabetes Care, Inc. | 2 | $45 |
| Sanofi | 1 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Dexcom, Inc. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $26 |
| QOL Medical, LLC | 1 | $20 |
| Nevro Corp. | 1 | $19 |
| Celltrion USA Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Exact Sciences | 1 | $13 |
| BETA Bionics, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$125
How this compares
$1,831 in reported general payments places this provider in the 85th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 311 | $404,144 |
| OzempicSemaglutide | 223 | $365,542 |
| TrulicityDulaglutide | 153 | $203,718 |
| JardianceEmpagliflozin | 103 | $130,918 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $55,661 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $54,614 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 46 | $41,392 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 25 | $31,073 |
| JanuviaSitagliptin Phosphate | 18 | $16,317 |
| Humulin R U-500Insulin Regular, Human | 11 | $15,305 |
| TradjentaLinagliptin | 13 | $14,947 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $14,128 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $13,663 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $11,886 |
| Victoza 3-PakLiraglutide | 11 | $11,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $54 | $615,462487 claims |
| Novo NordiskOzempic, Novolog | $106 | $371,446239 claims |
| Boehringer IngelheimJardiance, Tradjenta | $16 | $145,865116 claims |
| AbbVieSynthroid | $242 | $1,06111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,320 family providers in Massachusetts.
Other family in Danvers
- Rochelle NazarianDanvers$31K
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.